Temporal Trends of Cardiac Outcomes and Impact on Survival in Patients with Cancer.

Hussain, Muzna; Hou, Yuan; Watson, Chris; Moudgil, Rohit; Shah, Chirag; Abraham, Jame; Budd, G Thomas; Tang, W H Wilson; Finet, J Emanuel; James, Karen; Estep, Jerry D; Xu, Bo; Hu, Bo; Cremer, Paul; Jellis, Christine; Grimm, Richard A; Greenberg, Neil; Popovic, Zoran B; Cho, Leslie; Desai, Milind Y; Nissen, Steven E; Kapadia, Samir R; Svensson, Lars G; Griffin, Brian P; Cheng, Feixiong; Collier, Patrick

To evaluate the temporal relationships of cardiovascular disease in oncology patients referred to cardio-oncology and describe the impact of cardiovascular disease and cardiovascular risk factors on outcomes. All adult oncology patients referred to the cardio-oncology service at the Cleveland Clinic from January 2011 up to June 2018 were included in the study. Comprehensive clinical information were collected. The impact on survival of temporal trends of cardiovascular disease in oncology patients were assessed with a Cox proportional hazards model and time-varying covariate adjustment for confounders. In total, 6,754 patients were included in the study (median age, 57 years; [interquartile range, 47-65 years]; 3,898 women [58%]; oncology history [60% - breast cancer, lymphoma and leukemia]). Mortality and diagnosis of clinical cardiac disease peaked around the time of chemotherapy. 2,293 patients (34%) were diagnosed with a new cardiovascular risk factor after chemotherapy, over half of which were identified in the first year after cancer diagnosis. Patients with pre-existing and post-chemotherapy cardiovascular disease had significantly worse outcomes than patients that did not develop any cardiovascular disease (p<0.0001). The highest one-year hazard ratios [HR] of post-chemotherapy cardiovascular disease were significantly associated with male [HR 1.81; 95% CI 1.55-2.11; p<0.001] and diabetes [HR 1.51; 95% CI 1.26-1.81; p<0.001]. In conclusion, patients referred to cardio-oncology, first diagnosis of cardiac events peaked around the time of chemotherapy. Those with pre-existing or post-chemotherapy cardiovascular disease had worse survival. In addition to a high rate of cardiovascular risk factors at baseline, risk factor profile worsened over course of follow-up.